Advanced search
Publication Cover
Acta Obstetricia et Gynecologica Scandinavica Volume 81, 2002 - Issue 9
Journal homepage
1
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Consequenses for HRT following the HERS II and WHI reports: The primum non nocere is important, but translation into quo vadis is even more essential

Sven O. Skouby
Pages 793-798 | Published online: 07 Aug 2009

References

  • Mendelsohn ME, Karas R. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340: 1801–11.
  • Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: 1016–37.
  • Grodstein F, Stamfer MJ, Coldiz GA, Willet WC, Manson JE, Joffe M et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769–75.
  • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. (for the HERS Research Group). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart Estrogen/Progestin Replacement Study (HERS) Res Group. JAMA 1998;280: 605–13.
  • Ylikorkala O. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution. Acta Obstet Gynecol Scand 2000;79: 1029–36.
  • Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343: 522–9.
  • Angerer P Stork S, Kothny W, Schmitt P von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21: 262–8.
  • Petitti DB. Hormone Replacement Therapy for Prevention. More Evidence, More Pessimism (Editorial). JAMA 2002;288: 99–101.
  • Mosca L, Collins P Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM et al. Hormone Replacement Therapy and Cardiovascular Disease. A Statement for Healthcare Professionals. Am Heart Assoc Circulation 2001;104: 499–503.
  • Grady D, Herrington D, Bitner V Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. Heart Estrogen/Progestin Replacement Study Follow-Up (HERS II) JAMA 2002;288: 49–57.
  • Hulley S, Furberg C, Barret-Connor E, Cauley J, Grady D, Haskell W et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. Heart Estrogen/Progestin Replacement Study Follow-Up (HERS II) JAMA 2002;288: 58–66.
  • Writing Group for the Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA 2002;288: 321–33.
  • Fletcher SW, Colditz GA. Failure Estrogen Plus Progestin Theray for Prevention (Editorial) JAMA 2002;288: 366–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.